Great Lakes Advisors LLC Invests $972,000 in Harrow, Inc. (NASDAQ:HROW)

Great Lakes Advisors LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) in the 4th quarter, HoldingsChannel reports. The fund acquired 28,963 shares of the company’s stock, valued at approximately $972,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Quest Partners LLC acquired a new position in shares of Harrow during the 3rd quarter worth about $29,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the period. HighTower Advisors LLC boosted its position in shares of Harrow by 13.8% in the 4th quarter. HighTower Advisors LLC now owns 10,127 shares of the company’s stock valued at $340,000 after purchasing an additional 1,227 shares during the period. AlphaQuest LLC boosted its position in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock valued at $118,000 after purchasing an additional 2,889 shares during the period. Finally, Calamos Advisors LLC boosted its position in shares of Harrow by 35.2% in the 4th quarter. Calamos Advisors LLC now owns 11,913 shares of the company’s stock valued at $400,000 after purchasing an additional 3,103 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Stock Up 3.5 %

Harrow stock opened at $23.01 on Friday. Harrow, Inc. has a twelve month low of $9.30 and a twelve month high of $59.23. The stock has a 50 day moving average of $30.45 and a two-hundred day moving average of $38.85. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock has a market capitalization of $819.50 million, a price-to-earnings ratio of -24.48 and a beta of 0.69.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HROW. HC Wainwright began coverage on Harrow in a research report on Thursday, February 6th. They issued a “buy” rating and a $57.00 target price for the company. B. Riley reduced their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.